The pharmaceutical... Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ ...

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical ... The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to ...

Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyroid ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

aDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain bDepartment of Hematology and Oncology, Fox Chase ...

Get the latest news and real-time alerts from HOOKIPA Pharma Inc. (HOOK) stock at Seeking Alpha. Skip to content Home page Seeking Alpha - Power to Investors About Premium Explore Alpha Picks Home ...

Find out the direct holders, institutional holders and mutual fund holders for HOOKIPA Pharma Inc. (HOOK). ... Gilead Sciences Inc 1.88M Mar 31, 2025 19.16% 2,832,676 Baker Bros. Advisors, LP 812.81k ...